Posted in:News PTAB Denies Sandoz’s IPR Petition for Humira®-Related Patent By Caitlin M. Wilmot May 17, 2018 Comments are off Earlier this month, the Patent Trial and Appeal Board (“PTAB” or “the Board”) denied institution of Sandoz’s petition for inter... Read more Tagged with: AbbVie, Humira®, IPR, News, PTAB, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News FDA Approves Retacrit as a Biosimilar to Epogen® By Seth Cockrum May 15, 2018 Comments are off Today, the FDA announced that it approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen® for the treatment of anemia caused by... Read more Tagged with: Amgen, Epogen®, FDA, Hospira, News, Pfizer, Retacrit® http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News District Court Grants Genentech’s Motions to Dismiss Celltrion’s Declaratory Judgment Actions in Herceptin® and Rituxan®-Related Suits By Seth Cockrum May 11, 2018 Comments are off As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a number of patents... Read more Tagged with: BLA, BPCIA, Celltrion, District Court, Genentech, Herceptin®, News, Patent Dance, Rituxan®, Rituximab, trastuzumab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News PTAB Denies Inter Partes Review of Rituxan® Patents By D. Lawson Allen May 10, 2018 Comments are off The Patent Trial and Appeal Board (“the Board”) has decided not to institute inter partes review (“IPR”) on two patents owned by... Read more Tagged with: Biogen, Celltrion, Genentech, IPR, Pfizer, PTAB, Rituxan®, Rituximab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Sandoz Receives Complete Response Letter from FDA for Proposed Rituximab Biosimilar By Seth Cockrum May 7, 2018 Comments are off Sandoz announced last week that the FDA issued a complete response letter for its proposed biosimilar to rituximab. In the announcement,... Read more Tagged with: FDA, News, Rituximab, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Final Judgment Entered in Amgen v. Coherus Neulasta Litigation By Seth Cockrum April 26, 2018 Comments are off Last week, on April 18, 2018, Judge Stark in the District of Delaware entered the Final Judgment and Order dismissing the patent... Read more Tagged with: Amgen, BLA, BPCIA, Coherus, Neulasta®, pegfilgrastim http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Fujifilm and Mylan Announce Partnership to Commercialize Adalimumab Biosimilar By Seth Cockrum April 20, 2018 Comments are off Fujifilm Kyowa Kirin Biologics Co., Ltd. (“Fujifilm”) recently announced that it will partner with Mylan N.V. (“Mylan”) to... Read more Tagged with: adalimumab, EMA, Fujifilm Kyowa Kirin, Mylan, News http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus